Reactivating p53 mutants selectively in patients

A commentary published in Cancer Cell highlights encouraging clinical results for rezatapopt, a small-molecule reactivator of mutant p53, recently reported in the New England Journal of Medicine. The tumor suppressor p53 is the most frequently mutated protein across human cancers and has long been considered an undruggable target, making any clinically meaningful progress against it a landmark event. Rezatapopt works by selectively restoring the function of a common p53 mutant, offering a precision-medicine approach that could benefit a broad patient population. While the authors describe the findings as an encouraging step rather than a definitive proof of clinical utility, the results represent a significant advance in the decades-long effort to therapeutically exploit p53 loss of function.